Deerfield Management Company, L.P. (Series C) Merus N.V. Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Merus N.V. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,173,928 shares of MRUS stock, worth $214 Million. This represents 3.38% of its overall portfolio holdings.
Number of Shares
3,173,928
Previous 2,972,787
6.77%
Holding current value
$214 Million
Previous $125 Million
6.87%
% of portfolio
3.38%
Previous 3.1%
Shares
12 transactions
Others Institutions Holding MRUS
# of Institutions
196Shares Held
62.2MCall Options Held
355KPut Options Held
96.5K-
Wellington Management Group LLP Boston, MA4.72MShares$318 Million0.04% of portfolio
-
Commodore Capital LP New York, NY4.47MShares$302 Million18.43% of portfolio
-
Rtw Investments, LP New York, NY4.17MShares$281 Million2.88% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.37MShares$227 Million7.27% of portfolio
-
Avoro Capital Advisors LLC New York, NY3MShares$202 Million2.04% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $3.09B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...